LIPUM AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.85 SEK | -4.88% |
|
-12.69% | -10.28% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Lipum AB (publ) is a Sweden-based biopharmaceutical company specialized in discovery and development of new treatment for chronic inflammatory diseases. Lipum develops new biological medicine for treatment of chronic inflammatory diseases eg rheumatoid arthritis. Development is based on results from preclinical research, for example in well-established animal models for inflammatory arthritis. The prospective drug is an antibody directed against a new target molecule, the protein Bile Salt-Stimulated Lipase (BSSL). Lipum's antibody (SOL-116) has a different mechanism of action than the other drugs. Lipum's drug candidate SOL-116 is a humanized monoclonal antibody and is therefore categorized as a biological drug.
Sector
Pharmaceuticals
Calendar
2024-04-28
- LSX World Congress
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.28% | 5.25M | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -19.27% | 29.48B | |
| +57.86% | 25.43B | |
| -17.69% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
- Stock Market
- Equities
- LIPUM Stock
- News Lipum AB
- Lipum : Initiates Final Toxicology Study Of Chronic Inflammation Drug
